pulmonary embolism

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

antithrombotics

not classified
BARRIT, 1960   anticoagulantno anticoagulantsuggesting-80%
CASSIOPEA, 2012      NCTidrabiotaparinuxwarfarinLow risk of bias negative
OTPE (Aujesky), 2011      NCToutpatient treatmentinpatient treatmentRisk of bias negative+Infini%-2%
Otero, 2010      NCToutpatient treatmentinpatient treatmentRisk of bias negative-17%-50%
apixaban
AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting-51%
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting-75%
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-69%-21%
Certoparin
Certoparin-Study Group sub group, 1998   Certoparinunfractionated heparinExploratory negative
dalteparin
Kuijer, 1995   Dalteparinunfractionated heparinnegative
Meyer, 1995   Dalteparinunfractionated heparinnegative
enoxaparin
PREPIC, 1998     Enoxaparinunfractionated heparinRisk of bias negative
Merli sub group, 2001     Enoxaparinunfractionated heparinExploratory negative
fondaparinux
MATISSE PE, 2003   fondaparinuxheparinRisk of bias negative-15%19%
idraparinux
VanGogh PE, 2007    NCTidraparinux (without heparin)heparin/VKARisk of bias negative -49%79%
nadroparin
European multicentre study, 1991   Nadroparinunfractionated heparinRisk of bias negative
Prandoni sub-group, 1992       Nadroparinunfractionated heparinExploratory negative
Thery, 1992   Nadroparinunfractionated heparinExploratory negative
reviparin
COLOMBUS sub group, 1997     Reviparinunfractionated heparinExploratory negative
rivaroxaban
Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -
tinzaparin
ACTSG (Hull) sub-group, 1992     Tinzaparinunfractionated heparinLow risk of bias negative
THESEE, 1997     Tinzaparinunfractionated heparinRisk of bias negative
Campbell, 1998   Tinzaparinunfractionated heparinnegative

fibrinolysis

not classified
MOPETT, 2012   half-dose t-PAno fibrinolysis -
candesartan
Tebbe, 2009     desmoteplasealteplaseExploratory -
rt-PA
PAIMS 2, 1992   rt-PAno fibrinolysisExploratory negative20%60%
Goldhaber, 1993   rt-PAno fibrinolysisExploratory negative259%-100%
PIOPED, 1990     rt-PAplaceboLow risk of bias negative+Infini%+Infini%
Levine, 1990     rt-PAplaceboLow risk of bias negative +Infini%
Konstantinides, 2002     rt-PAplaceboLow risk of bias negative-77%56%
streptokinase
Tibbutt, 1974   streptokinaseno fibrinolysisExploratory negative31%-100%
Ly, 1978   streptokinaseno fibrinolysisExploratory negative57%-61%
Jerjes-Sanchez, 1995   streptokinaseno fibrinolysisExploratory -
urokinase
Marini, 1988   urokinaseno fibrinolysisExploratory -
UPET, 1973   urokinaseplaceboLow risk of bias negative90%-18%